Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
CVRX
vs
S&P 500
S&P 500
Over the past 12 months, CVRX has underperformed S&P 500, delivering a return of -86% compared to S&P 500's +11% growth.
Stocks Performance
CVRX vs S&P 500
Performance Gap
CVRX vs S&P 500
Performance By Year
CVRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CVRx Inc
Glance View
CVRx makes an implantable medical device called Barostim, which uses electrical stimulation to activate baroreceptors in the neck. The therapy is designed to help patients with heart failure and high blood pressure when medicines are not enough. In simple terms, it is a device-based treatment that works by changing how the nervous system controls the heart and blood vessels. The company sells its system to hospitals and physicians, who implant and manage the device for patients. Its revenue comes mainly from selling the implantable generator, leads, and related system components, along with the support and training needed to use the therapy. The main customers are healthcare providers treating advanced cardiovascular disease. CVRx sits in a specialized corner of the medical device industry: neuromodulation for cardiovascular care. That makes its business different from drug makers, because it depends on physician adoption of a procedure and long-term use of an implanted device rather than repeat prescriptions. Its success depends on whether doctors see the therapy as a useful option for patients who need another treatment path beyond standard medicines.